Racing ahead to beat cancer

Developing the next generation of medicines that will lead the fight against cancer
Read More Our Pipeline

Cancer cells evolve, so does our science

Relentless and innovative thinking that keeps our science one step ahead, always!

Our Science

Time is of the essence and we will be ready

full pipeline

We are all in to make it possible

Publications

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3K δ/ γ Inhibitor in Patients with Relapsed/Refractory Lymphoid Malignancies

Read More +

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Read More +

Addition of RP6530, a dual PI3Kδ/γ inhibitor, accentuates Romidepsin activity in NHL cells in vitro

Read More +

Safety and Anti-Tumour Activity of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

Read More +

Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathway

Read More +

Store-operated calcium signaling is an effective therapeutic target in Acute Myeloid Leukemia (AML)

Read More +

Partner With Us

Our approach to partnering is simple and yet effective. We are looking to collaborate with partners having synergistic capabilities and programs. Our successful track record of partnerships with the likes of TG Therapeutics, Novartis etc., bear testimony to our win-win approach.

We have an affiliate entities & offices located across US, EU and India to facilitate our collaborative approach to a developing & commercializing a globally competitive pipeline.

Contact Us